OXiGENE to Webcast First-Quarter 2004 Financial Results Conference Call; Live Internet Webcast to be Available at www.oxigene.com.Business Editors/Health/Medical Writers WALTHAM, Mass.--(BUSINESS WIRE)--April 14, 2004 OXiGENE, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : OXGN, XSSE: OXGN), a leader in the development of biopharmaceutical compounds designed to target aberrant blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. in solid tumor cancers and ocular neovascular diseases, invites the public to listen to a live audio webcast of the Company's first-quarter 2004 financial results conference call at 10:00 a.m. ET Wednesday, April 28, 2004. The call will be hosted by President and Chief Executive Officer Fred Driscoll, Chief Financial Officer James Murphy James Murphy may refer to:
OXiGENE plans to announce its first-quarter 2004 financial results on April 28, prior to the opening of the NASDAQ Stock Market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. . To listen to a live or an archived version of the webcast, please log on to the Company's website, www.oxigene.com. Under the "Investor Center" tab, click on the link to "Presentations & Conference Calls." OXiGENE's first-quarter conference call also can be heard live by dialing 888-208-1814 (domestic) or 719-457-2655 (international) five minutes prior to the call. A replay of the call will be available beginning approximately two hours after the call and ending at midnight ET Tuesday, May 4. To access the replay, dial 888-203-1112 (domestic) or 719-457-0820 (international) and refer to reservation number 640356. About OXiGENE OXiGENE is the world leader in the development of vascular targeting agents (VTAs), novel biopharmaceutical compounds designed to selectively target and destroy new blood vessels. The Company's lead compound, Combretastatin A4 Prodrug prodrug /pro·drug/ (-drug) a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent; a precursor of a drug. (CA4P), is in clinical development in patients with solid tumor cancers and wet age-related macular degeneration Age-related macular degeneration (ARMD) Degeneration of the macula (the central part of the retina where the rods and cones are most dense) that leads to loss of central vision in people over 60. . Three other OXiGENE VTAs, OXi4503, OXi6197 and OXi8007, are in pre-clinical development. For more information about OXiGENE, visit www.oxigene.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion